Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G Endures 'Top-Line Pain' As Portfolio Streamlining Prioritizes Premium Products

This article was originally published in The Tan Sheet

Executive Summary

The firm reports slumps between 1% and 5% across each of its product categories, but also encourages analysts with reports of sometimes significant progress in its "transformation" initiatives in productivity, portfolio, organization and top-line growth.

You may also be interested in...



P&G Eyes Targeted Innovation, China Opportunities Amid Transformation

CFO Jon Moeller drives home that P&G is "operating in a more volatile environment than we ever have" as it continues shedding slow-growth brands. Hair care and grooming are high among the streamlined company's strategic priorities, as well as the US market and China.

In Brief: Revlon Sale?; P&G/Coty Fragrance Transfer; More

SEC filing affirms Revlon is exploring strategic alternatives; Procter & Gamble will transfer 10 fragrance licenses to Coty. More news in brief.

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel